130 related articles for article (PubMed ID: 30858025)
1. The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors.
Deaton DN; Do Y; Holt J; Jeune MR; Kramer HF; Larkin AL; Orband-Miller LA; Peckham GE; Poole C; Price DJ; Schaller LT; Shen Y; Shewchuk LM; Stewart EL; Stuart JD; Thomson SA; Ward P; Wilson JW; Xu T; Guss JH; Musetti C; Rendina AR; Affleck K; Anders D; Hancock AP; Hobbs H; Hodgson ST; Hutchinson J; Leveridge MV; Nicholls H; Smith IED; Somers DO; Sneddon HF; Uddin S; Cleasby A; Mortenson PN; Richardson C; Saxty G
Bioorg Med Chem; 2019 Apr; 27(8):1456-1478. PubMed ID: 30858025
[TBL] [Abstract][Full Text] [Related]
2. Development of a scintillation proximity binding assay for high-throughput screening of hematopoietic prostaglandin D2 synthase.
Meleza C; Thomasson B; Ramachandran C; O'Neill JW; Michelsen K; Lo MC
Anal Biochem; 2016 Oct; 511():17-23. PubMed ID: 27485270
[TBL] [Abstract][Full Text] [Related]
3. The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure.
Cadilla R; Deaton DN; Do Y; Elkins PA; Ennulat D; Guss JH; Holt J; Jeune MR; King AG; Klapwijk JC; Kramer HF; Kramer NJ; Laffan SB; Masuria PI; McDougal AV; Mortenson PN; Musetti C; Peckham GE; Pietrak BL; Poole C; Price DJ; Rendina AR; Sati G; Saxty G; Shearer BG; Shewchuk LM; Sneddon HF; Stewart EL; Stuart JD; Thomas DN; Thomson SA; Ward P; Wilson JW; Xu T; Youngman MA
Bioorg Med Chem; 2020 Dec; 28(23):115791. PubMed ID: 33059303
[TBL] [Abstract][Full Text] [Related]
4. Identification of indole inhibitors of human hematopoietic prostaglandin D2 synthase (hH-PGDS).
Edfeldt F; Evenäs J; Lepistö M; Ward A; Petersen J; Wissler L; Rohman M; Sivars U; Svensson K; Perry M; Feierberg I; Zhou XH; Hansson T; Narjes F
Bioorg Med Chem Lett; 2015 Jun; 25(12):2496-500. PubMed ID: 25978964
[TBL] [Abstract][Full Text] [Related]
5. Biochemical, functional, and pharmacological characterization of AT-56, an orally active and selective inhibitor of lipocalin-type prostaglandin D synthase.
Irikura D; Aritake K; Nagata N; Maruyama T; Shimamoto S; Urade Y
J Biol Chem; 2009 Mar; 284(12):7623-30. PubMed ID: 19131342
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design.
Yokoo H; Shibata N; Endo A; Ito T; Yanase Y; Murakami Y; Fujii K; Hamamura K; Saeki Y; Naito M; Aritake K; Demizu Y
J Med Chem; 2021 Nov; 64(21):15868-15882. PubMed ID: 34652145
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase.
Aritake K; Kado Y; Inoue T; Miyano M; Urade Y
J Biol Chem; 2006 Jun; 281(22):15277-86. PubMed ID: 16547010
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
Weber JE; Oakley AJ; Christ AN; Clark AG; Hayes JD; Hall R; Hume DA; Board PG; Smythe ML; Flanagan JU
Eur J Med Chem; 2010 Feb; 45(2):447-54. PubMed ID: 19939518
[TBL] [Abstract][Full Text] [Related]
9. Novel amide and imidazole compounds as potent hematopoietic prostaglandin D
Olson KL; Holt MC; Ciske FL; Kramer JB; Heiple PE; Collins ML; Johnson CM; Ho CS; Morano MI; Barrett SD
Bioorg Med Chem Lett; 2021 Feb; 34():127759. PubMed ID: 33383152
[TBL] [Abstract][Full Text] [Related]
10. [Hematopoietic prostaglandin D synthase inhibitors for the treatment of duchenne muscular dystrophy].
Kamauchi S; Urade Y
Brain Nerve; 2011 Nov; 63(11):1261-9. PubMed ID: 22068479
[TBL] [Abstract][Full Text] [Related]
11. A knowledge-based, structural-aided discovery of a novel class of 2-phenylimidazo[1,2-a]pyridine-6-carboxamide H-PGDS inhibitors.
Schulte CA; Deaton DN; Diaz E; Do Y; Gampe RT; Guss JH; Hancock AP; Hobbs H; Hodgson ST; Holt J; Jeune MR; Kahler KM; Kramer HF; Le J; Mortenson PN; Musetti C; Nolte RT; Orband-Miller LA; Peckham GE; Petrov KG; Pietrak BL; Poole C; Price DJ; Saxty G; Shillings A; Smalley TL; Somers DO; Stewart EL; Stuart JD; Thomson SA
Bioorg Med Chem Lett; 2021 Sep; 47():128113. PubMed ID: 33991628
[TBL] [Abstract][Full Text] [Related]
12. High-quality crystals of human haematopoietic prostaglandin D synthase with novel inhibitors.
Takahashi S; Tsurumura T; Aritake K; Furubayashi N; Sato M; Yamanaka M; Hirota E; Sano S; Kobayashi T; Tanaka T; Inaka K; Tanaka H; Urade Y
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2010 Jul; 66(Pt 7):846-50. PubMed ID: 20606289
[TBL] [Abstract][Full Text] [Related]
13. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): a tale of two waters.
Trujillo JI; Kiefer JR; Huang W; Day JE; Moon J; Jerome GM; Bono CP; Kornmeier CM; Williams ML; Kuhn C; Rennie GR; Wynn TA; Carron CP; Thorarensen A
Bioorg Med Chem Lett; 2012 Jun; 22(11):3795-9. PubMed ID: 22546671
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic prostaglandin D synthase inhibitors.
Thurairatnam S
Prog Med Chem; 2012; 51():97-133. PubMed ID: 22520473
[No Abstract] [Full Text] [Related]
16. Inhibition of hematopoietic prostaglandin D2 synthase (H-PGDS) by an alkaloid extract from Combretum molle.
Moyo R; Chimponda T; Mukanganyama S
BMC Complement Altern Med; 2014 Jul; 14():221. PubMed ID: 24996417
[TBL] [Abstract][Full Text] [Related]
17. Human hematopoietic prostaglandin D synthase inhibitor complex structures.
Kado Y; Aritake K; Uodome N; Okano Y; Okazaki N; Matsumura H; Urade Y; Inoue T
J Biochem; 2012 Apr; 151(4):447-55. PubMed ID: 22418579
[TBL] [Abstract][Full Text] [Related]
18. NMR solution structure of lipocalin-type prostaglandin D synthase: evidence for partial overlapping of catalytic pocket and retinoic acid-binding pocket within the central cavity.
Shimamoto S; Yoshida T; Inui T; Gohda K; Kobayashi Y; Fujimori K; Tsurumura T; Aritake K; Urade Y; Ohkubo T
J Biol Chem; 2007 Oct; 282(43):31373-9. PubMed ID: 17715133
[TBL] [Abstract][Full Text] [Related]
19. L-type prostaglandin D synthase regulates the trafficking of the PGD
Binda C; Génier S; Degrandmaison J; Picard S; Fréchette L; Jean S; Marsault E; Parent JL
J Biol Chem; 2019 Nov; 294(45):16865-16883. PubMed ID: 31575663
[TBL] [Abstract][Full Text] [Related]
20. Lipocalin-type prostaglandin D synthase produces prostaglandin D2 involved in regulation of physiological sleep.
Qu WM; Huang ZL; Xu XH; Aritake K; Eguchi N; Nambu F; Narumiya S; Urade Y; Hayaishi O
Proc Natl Acad Sci U S A; 2006 Nov; 103(47):17949-54. PubMed ID: 17093043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
